Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Un nou sistem de endoscopică imaging are capacitatea de a detecta mai mulți fluorescent tracers.
2.
In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.
3.
Dual imaging capsule captures 3D tissue and blood vessel changes for early esophageal cancer diagnosis
4.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
5.
One-third of childhood cancer survivors experience significant fear that it could come back, study reveals
1.
Hypercoagulable State: Factors that Contribute to Blood Clots
2.
Understanding Verrucous Carcinoma: Symptoms, Diagnosis, and Treatment Options
3.
Interpreting Iron Studies: What Your Blood Results Really Mean
4.
The Capmist DM: A Revolutionary Way to Combat Dry Mouth
5.
The Basics of M.C.V Normal Range for Better Health Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Should We Use DARA Up Front As First-Line Therapy in MM?
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge